SCHEMBL5429147

SCHEMBL5429147

CCOC(=O)CN(Cc1ccc(OCCc2nc(-c3cccs3)oc2OC)cc1)S(=O)(=O)C1CCc2ccccc2N1

nearest known ligand 0.41

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 17/20 0.41
PPARG P37231 17/20 0.41
PPARD Q03181 3/20 0.39
KDM4E B2RXH2 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5269968 0.92 PPARA (0.41) PPARAPPARGPPARD
SCHEMBL5230142 0.89 PPARA (0.48) PPARAPPARGPPARDKDM4E
SCHEMBL5443595 0.87 PPARG (0.43) PPARAPPARGPPARD
SCHEMBL5224858 0.83 PPARG (0.53) PPARAPPARG
SCHEMBL5264951 0.82 PPARG (0.48) PPARAPPARG
SCHEMBL5226538 0.81 PPARA (0.48) PPARAPPARGPPARD
SCHEMBL5264762 0.81 PPARG (0.50) PPARAPPARG
SCHEMBL5428687 0.81 PPARA (0.42) PPARAPPARGPPARDKDM4E
SCHEMBL5262656 0.80 PPARA (0.48) PPARAPPARGPPARD
SCHEMBL5226126 0.80 PPARG (0.50) PPARAPPARGPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070254882-A1 Sulfamide Derivatives and Pharmaceutical Composition for Upregulation of Lipid Metabolism Comprising Same CRYSTAL GENOMICS, INC. (KR) 2007-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254882-A1 Sulfamide Derivatives and Pharmaceutical Composition for Upregulation of Lipid Metabolism Comprising Same SULT2A1, SPTLC2, SGMS2 PPARA 190/4885PPARG 399/4885PPARD 210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.